



PRESS RELEASE

CARMAT appoints Valerie Leroy as Director of Marketing and Investor Relations

Paris, February 9th, 2011

CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart project, today announced the appointment of Valerie Leroy as Director of Marketing and Investor Relations. Her prime objective will be to raise Carmat's profile and impact with investors, the scientific community and the general public.

"Carmat's artificial heart project marks the advent of a new class of totally biocompatible and autonomous artificial organs. This is a technological breakthrough that meets real unmet clinical needs", emphasized Valerie Leroy.

Valerie Leroy started her career in IT sales and marketing in 1984 and notably led Toshiba Systems France's key accounts team from 1988 until 1994. In 1996, she joined the marketing team of Medtronic for the Cardiac Rhythm Management portfolio. In 2001, Valerie joined Edwards Lifesciences, where she held a variety of management positions in marketing and sales for over 9 years at the EMEA headquarters in Switzerland and the global headquarters in Irvine, CA. From 2008 to 2010, she served as Director of Marketing, EMEA, for the company's surgical heart valve therapy product line (valve repair and bioprotheses).

"We are delighted to welcome Valerie to Carmat. She will provide the company with the benefit of her extensive European and global experience of marketing and business development. Accordingly, Valerie will play a key role in continuing to build a targeted, structured corporate communication strategy", commented Carmat CEO Marcello Conviti.

Valerie Leroy holds a Masters in Marketing from Paris Pantheon-Sorbonne University Business School (1996).

About CARMAT: CARMAT, the world's most advanced total artificial heart project

The only credible response for all cases of end-stage heart failure, which is a real public health issue:

CARMAT's aim is to be able to provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 100 million patients in developed countries. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.

The result of the combination of two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of EADS, world aerospace leader.

Imitating the natural heart: given its size, its weight, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life.

A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by OSEO; a total of €33 million.

Substantial involvement of prestigious founders and shareholders: Truffle Capital, the leading European venture capital firm, EADS, the Foundation Alain Carpentier (Carmat's co-founder) and thousands of institutional and individual shareholders who have also shown their confidence in CARMAT.

Carmat's Board of Directors is constituted by André-Michel Ballester, Jean-Claude Cadudal (Chairman), Professor Alain Carpentier, Michel Finance, Henri Lachmann, Marcello Conviti and Philippe Pouletty MD.

For more information: www.carmatsas.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Carmat ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French *Autorité des marchés financiers* ("AMF") granted its visa number 10-180 on June 14, 2010, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.



CARMAT

Marcello Conviti

CEO

Patrick Coulombier

COO

Tel.: + 33 (0)1 39 45 54 50

investors@carmatsas.com

NewCap.

Financial Communication & Investor relations

Axelle Vuillermet / Emmanuel Huynh

Tel.: 01 44 71 94 94

carmat@newcap.fr



Name: **CARMAT**
ISIN code: **FR0010907956**
Ticker: **ALCAR**